



► BIOPHARMA POOL

David Allsop AMICUS THERAPEUTICS APPOINTS SENIOR VP, INTERNATIONAL



David Allsop

Amicus Therapeutics, a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, has appointed David Allsop as senior VP, international. He is responsible for Amicus' international organizational

build out, and is leading international commercial and market access activities for migalastat monotherapy for Fabry disease.

Before joining Amicus, Mr. Allsop was instrumental in building Biogen's international commercial organization over the last 17 years.

Dr. Lakhmir Chawla LA JOLLA PHARMACEUTICAL NAMES CHIEF MEDICAL OFFICER



Dr. Lakhmir Chawla

La Jolla Pharmaceutical, which is developing innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, has appointed Lakhmir Chawla, M.D., chief

medical officer.

Dr. Chawla is currently an associate professor of medicine at the George Washington University, where he has dual appointments in the Department of Anesthesiology and Critical Care Medicine and in the Department of Medicine, Division of Renal Diseases and Hypertension. Dr. Chawla is also currently the chief of the division of intensive care medicine at the Washington, D.C., Veterans Affairs Medical Center.

Drew Fromkin BLEND THERAPEUTICS APPOINTS PRESIDENT AND CEO



Drew Fromkin

Blend Therapeutics, a biopharmaceutical company discovering and developing two distinct classes of targeted anti-cancer medicines to advance the treatment of patients with solid tumor cancers, has appointed Drew

Fromkin president and CEO.

Mr. Fromkin previously served as president and CEO of Clinical Data, until its acquisition by Forest Laboratories.

Dr. Jeremy Levin OVID THERAPEUTICS NAMES CEO

Ovid Therapeutics, a privately held biopharma-



Dr. Jeremy Levin

ceutical company focused on developing therapies for rare and orphan diseases of the brain, has appointed Jeremy Levin, BMBS, as CEO. Dr. Levin has served as chairman of Ovid since 2014 and will continue to serve in this

role.

Dr. Levin has more than 25 years of experience in the global pharmaceutical industry, leading companies and people to develop and commercialize medicines that address compelling medical needs worldwide. Most recently, Dr. Levin served as president and CEO of Teva Pharmaceutical Industries.

Chen Schor SYNTA NAMES PRESIDENT, CEO



Chen Schor

Synta Pharmaceuticals has promoted Chen Schor from executive VP, chief operating officer, to president and CEO. Mr. Schor replaces Anne Whitaker, who is stepping down from her roles at Synta.

Mr. Schor has more than 15 years of leadership experience in biotechnology, medical devices, business development, and private equity.

► BIOTECH POOL

Jeff Goater VOYAGER THERAPEUTICS ANNOUNCES PROMOTION



Jeff Goater

Voyager Therapeutics, a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS), today announced the appointment of Jeff Goater, former VP of business development, to senior VP, finance and business development.

In this new role, Mr. Goater is responsible for overseeing finance, business development, and investor and public relations activities across the company.

► DIAGNOSTICS POOL

Mark Carbeau INTERLEUKIN GENETICS APPOINTS CEO

Interleukin Genetics has named Mark Carbeau as



Mark Carbeau

CEO. Mr. Carbeau is a transformative healthcare leader who brings to Interleukin more than three decades of business expertise in the life-science industries, with a proven track record of building high-growth diagnostic and pharmaceutical businesses.

Before joining Interleukin, Mr. Carbeau was co-founder and CEO of Diagnostyx, a technology-based healthcare company focused on intelligent drug infusion systems.

► AGENCY POOL

Michael Austin Louis Massaia PALIO PASSES LEADERSHIP TORCH



Michael Austin

Palio, an inVentiv Health advertising agency, in announcing that Chief Creative Global Officer Guy Mastrion has departed the agency, has named Michael Austin and Louis Massaia to lead the agency's bicoastal creative teams in California (Irvine and Santa Monica) and New York (New York City and Saratoga Springs).



Louis Massaia

Mr. Austin and Mr. Massaia have worked together for years at top-tier agencies, most recently as senior VP/creative directors at The CementBloc.

► SERVICE POOL

Eric Green CEO OF WEST PHARMACEUTICAL SERVICES NAMED



Eric Green

West Pharmaceutical Services, a provider of solutions for injectable drug administration, has appointed Eric M. Green as the company's CEO succeeding Donald E. Morel, Jr., Ph.D. Mr. Green joins West from Sigma-Aldrich Corp., where he has served as executive VP and president of the research markets business unit since 2013. ^{PV}



FOR BONUS CONTENT
USE YOUR QR CODE READER
OR GO TO
bit.ly/PV0615-Pool



► PHARMA POOL

Dr. Stephen Farr
ZOGENIX NAMES CEO

Zogenix, a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, has named Stephen Farr, Ph.D., as CEO to oversee its succession plan as the company focuses on advancing its late-stage product development pipeline.

Dr. Farr previously served as the company's president.

► BIOPHARMA POOL

Dr. Mark Manfredi
RAZE THERAPEUTICS APPOINTS CHIEF SCIENTIFIC OFFICER

Raze Therapeutics, a next-generation cancer metabolism company, has appointed Mark Manfredi, Ph.D., as chief scientific officer.

Dr. Manfredi joins Raze with nearly two decades of experience in cancer biology, having served most recently as VP, oncology biology, at Takeda Pharmaceuticals.

Eric Pauwels
PTC THERAPEUTICS NAMES SENIOR VP AND GENERAL MANAGER COMMERCIAL OPERATIONS, AMERICAS

PTC Therapeutics has appointed Eric Pauwels senior VP and general manager commercial operations, Americas. Mr. Pauwels is responsible for the commercial strategy, organizational build out, and launch of Translarna in the United States, Canada, and Latin America.

He brings 33 years of global healthcare experience from several top-tier U.S. and global pharmaceutical companies. Most recently, Mr. Pauwels was the chief commercial officer at NPS Pharmaceuticals and president of NPS Pharmaceuticals International.

Dr. Joseph Sarret
CORIUM APPOINTS CHIEF BUSINESS OFFICER
Corium International, a commercial-stage biopharmaceutical company focused on the development, manufacture, and commercialization of specialty transdermal products, has named Joseph Sarret, M.D., to the newly created position of chief business officer.

Most recently, Dr. Sarret served as senior VP, strategic accounts, at Solazyme, a publicly traded company focused on developing renewable products for a variety of industries.

► BIOTECH POOL

Dr. Alla Danilkovitch
OSIRIS THERAPEUTICS NAMES CHIEF SCIENTIFIC OFFICER

Osiris Therapeutics, a cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopedic, and sports medicine markets has promoted Alla Danilkovitch, Ph.D., to serve as chief scientific officer.

Dr. Danilkovitch has been with Osiris since 2003; her expertise and leadership have guided the company in the development of groundbreaking scientific ideas in regenerative medicine.

Dr. Rhett Schiffman
ENVISIA THERAPEUTICS NAMES CHIEF MEDICAL OFFICER

Envisia Therapeutics has named Rhett M. Schiffman, M.D., chief medical officer and senior VP of development. Before Envisia, Dr. Schiffman was the chief medical officer at Neurotech Pharmaceuticals, where he led the company's NT-503 program, a cell-based therapy for wet age-related macular degeneration (AMD), through its Phase I/II studies. He brings with him more than 20 years of expertise and achievements in ophthalmology.

Envisia Therapeutics, formed by Liquidia Technologies in 2013, is a privately held biotechnology company focused on the development of novel ocular therapies.

► SPECIALTY POOL

Dr. Louis Brenner
ALLENA PHARMACEUTICALS APPOINTS CHIEF OPERATING OFFICER

Allena Pharmaceuticals, a specialty biopharmaceutical company focused on developing and commercializing innovative, non-systemic, oral protein therapeutics to treat metabolic and orphan diseases, has named Louis Brenner, M.D., chief operating officer. Dr. Brenner brings to Allena more than a decade of industry leadership experience, including pharmaceutical clinical development strategy, regulatory affairs, business development, and marketing.

Dr. Brenner joins Allena from Idera Pharmaceuticals, where he served as senior VP and chief medical officer.

Scott Briggs
NOVEN BOLSTERS SALES AND MARKETING
Noven Pharmaceuticals has appointed Scott Briggs as the company's new VP, marketing and

sales, succeeding Andrew Panagy, who is retiring. In this role, Mr. Briggs is responsible for all marketing and sales activities at Noven and Noven Therapeutics, the company's specialty pharmaceutical business unit.

Michael Logerfo
SAGENT PHARMACEUTICALS NAMES PRESIDENT

Sagent Pharmaceutical, a leader of specialty pharmaceutical products with an emphasis on the injectable market, has promoted Michael Logerfo, executive VP and chief legal officer, to president.

John Thomas
HORIZON PHARMA NAMES EXECUTIVE VP, STRATEGY AND INVESTOR RELATIONS

Horizon Pharma, a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring, and commercializing differentiated products that address unmet medical needs has named John Thomas executive VP, strategy and investor relations.

Mr. Thomas is the former VP of investor relations and public affairs for Abbott, where he counseled the senior executive team on the financial community's expectations regarding major acquisitions, divestitures, strategic partnerships, research and development and ongoing business performance.

► AGENCY POOL

Tom Clark
Archie Robinson
PUBLICIS TOUCHPOINT SOLUTIONS MAKES TWO EXECUTIVE APPOINTMENTS

Publicis Touchpoint Solutions, a provider of customized, omni-channel healthcare sales, service, and clinical teams, has promoted Tom Clark into the role of executive VP of business development, having formerly served as VP of sales, leading Touchpoint's field teams. Mr. Clark has more than 25 years of experience in the biopharmaceutical industry. He joined Touchpoint in 2012 as national business director for a key field sales team execution.

Archie Robinson has been promoted to VP of sales and assumes overall responsibility for Touchpoint's field sales and service teams, client services, and sales training.

Mr. Robinson has more than 25 years of experience in the industry. He joined Touchpoint in 2011 as national sales director and in 2012 assumed the position of general manager leading a key commercial organization. **PV**

Risk Integration and Quality Management for Medical Device

Effectively Stratifying Risk throughout the Product Lifecycle

July 22-23, 2015
San Diego, CA

[More Registration Details, Click Here!](#)

Pre-Conference Workshop: July 21, 2015

Workshop: Developing a Robust System to Improve the Stratification of Risk Management with **Allergan**

Attending this Premier marcus evans Conference Will Enable You To:

- **Develop** a robust and integrated risk management plan to improve quality management and product success
- **Revitalize** risk reporting to enhance management and mitigation effects
- **Anticipate** and **React** to changes and updates in risk management requirements to ensure compliance
- **Establish** the vitality of risk management to improve functionality
- **Synthesize** risk management efforts with those of regulatory and notified bodies to streamline compliance efforts
- **Formalize** a proactive approach to risk management to advance mollification
- **Enhance** performance in FDA audits and inspections to ensure compliance with changes in ISOs 13485 and 14971
- **Unify** international regulations to improve performance in foreign markets
- **Sustain** an effective and integrated risk management strategy to increase confidence and efficacy
- **Navigate** global and technological regulatory changes to keep abreast of market needs

Who Should Attend:

marcus evans invites C-Level Executives, EVPs, SVPs, VPs, Directors, Heads and other senior executives from industries responsible for:

- Quality Assurance
- Risk Management
- Regulatory Affairs
- CAPA
- Quality Control
- Manufacturing
- Quality Systems
- Process Development
- Compliance

Platinum Sponsor:

PathWise

Media Partners:

ComplianceOnline
The Largest GRC Advisory Network

JOURNAL of MEDICAL DEVICE REGULATION

PharmaVOICE

Medical News TODAY

MEDEC
CANADA'S MEDICAL TECHNOLOGY COMPANIES
LES SOCIÉTÉS CANADIENNES DE TECHNOLOGIES MÉDICALES

Singularity in risk management is a risk not worth taking

Integrate a holistic strategy to mitigate risks and emerge as a leader in quality.

marcusevans

Featuring Sessions from Leading Medical Device Professionals Including:

Sharon Kapsch
Chief, MDR Policy Branch Office of Surveillance and Biometrics Center for Devices and Radiological Health
US Food and Drug Administration

Marc Wilson
Public Health Analyst Chief, MDR Policy Branch Office of Surveillance and Biometrics Center for Devices and Radiological Health
US Food and Drug Administration

Judith O'Grady
Corporate Vice President of Global Regulatory Affairs
Integra Life Sciences

Manfred Walder
Vice President, Quality Systems
Zimmer

Paul Landesman
Vice President of Quality, Regulatory, and Customer Service
Dictum Health

Larry Kopyta
Vice President of Quality Assurance and Regulatory Affairs
Omnyx

Gopal Mohanty
Director of Regulatory and Quality
Beckman Coulter

Christopher Slimak
Director of Quality Assurance – New Product Development
Zimmer

James Wabby
Director of Strategic Regulatory Compliance and Intelligence
Allergan

Ryan Magee
Senior Quality Manager, Risk Management and Biocompatibility
Fresenius Medical Care

Barb Young
Quality Engineer
Siemens Healthcare Diagnostics

Orlando Guillory
Director, Quality Engineering
Edwards Life Sciences

Marcelo Trevino
Senior Manager Quality Systems and Regulatory Compliance - Cardiac and Vascular Group
Medtronic

Janice Hardy
Director of Quality Assurance & Regulatory Affairs
Agena Bioscience

marcusevans conferences

Contact:
Monique Filardi | T: 312 625 0164
E: moniquef@marcusevansch.com